- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 285/135 - Atomes d'azote
Détention brevets de la classe C07D 285/135
Brevets de cette classe: 250
Historique des publications depuis 10 ans
|
22
|
26
|
19
|
15
|
17
|
13
|
9
|
8
|
5
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2713 |
11 |
| Bristol-myers Squibb Company | 4747 |
5 |
| The Regents of the University of California | 20790 |
5 |
| Boehringer Ingelheim International GmbH | 4487 |
5 |
| Abbott Laboratories | 2248 |
5 |
| Plexxikon Inc. | 146 |
5 |
| Vivoryon Therapeutics N.V. | 48 |
5 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2306 |
4 |
| Romark Laboratories L.C. | 44 |
4 |
| Sanofi | 4316 |
4 |
| Synhale Therapeutics Inc. | 4 |
4 |
| Board of Regents, The University of Texas System | 6127 |
3 |
| The Johns Hopkins University | 5898 |
3 |
| Purdue Research Foundation | 3926 |
3 |
| Asceneuron SA | 27 |
3 |
| Betagenon AB | 24 |
3 |
| The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | 120 |
3 |
| Oryzon Genomics S.A. | 103 |
3 |
| The Scripps Research Institute | 1342 |
3 |
| Lead Pharma Holding B.V. | 20 |
3 |
| Autres propriétaires | 166 |